Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Apellis’ Syfovre for Treatment of GA Approved by FDA
The FDA has approved Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This marks the first time that patients with GA have an FDA-approved treatment option, which is a significant milestone…
Benefits Of Combination Drops On Glaucoma Management
When patients are diagnosed with glaucoma, one of the most common treatment options is a prescription eye drop medication that lowers eye pressure, which prevents damage to the optic nerve and helps to preserve vision. Several types of drugs lower…
A Next-Gen Monofocal IOL From Johnson & Johnson Vision
Johnson & Johnson Vision Announces Launch of TECNIS Eyhance™ Toric II IOL with TECNIS Simplicity™ Delivery System, a Next-Generation Monofocal Intraocular Lens for Cataracts Patients with Astigmatism, in Europe TECNIS Eyhance™ Toric II IOL offers all the benefits associated with…
J&J announced new products at the AAO annual meeting
Johnson & Johnson Vision announced a series of new products and innovations at the 2019 American Academy of Ophthalmology (AAO) Annual Meeting in San Francisco, CA, USA. The company announced the US Food & Drug Administration (FDA) approval of the…
VSY Biotech Signs Agreement With WAKAMOTO Pharma
Leinfelden – Echterdingen, Germany March 19, 2021, VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology, visco supplementation in orthopedy and medical esthetics, announced today an agreement with WAKAMOTO PHARMACEUTICAL CO., LTD. (hereinafter refer to…
Updates On Central Serous Chorioretinopathy
Central serous chorioretinopathy, commonly referred to as CSC, is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. CSC most often occurs in young and middle-aged adults. For unknown reasons, men develop…
M1 Molecule: A Promising Treatment for Optic Nerve Injury
Traumatic injury to the central nervous system (CNS), spinal cord, and optic nerve is the primary cause of disability and the second largest cause of mortality worldwide. CNS injuries frequently result in catastrophic loss of sensory, motor, and visual skills,…
Topcon and OphtAI Collaborate for AI Technology
Topcon Healthcare Solutions and OphtAI, a joint venture specialized in Artificial Intelligence (AI) for ophthalmology, have announced a partnership to integrate OphtAI into Topcon’s Harmony Referral System, and provide eye care professionals with smarter access to AI services. OphtAI’s state-of-the-art…
Fungal Endophthalmitis Outbreak in South Korea
South Korean ophthalmologists reported a fungal endophthalmitis outbreak after cataract surgery due to contaminated viscoelastic material. Researchers from the Department of Ophthalmology at Korea University Guro Hospital in Seoul, Korea, under the direction of Seong Woo Kim, MD, PhD, found…
Vision Correction Market Report | OBN
According to recent market research by Allied Market Research, the global vision correction market was worth $20,302.8 million in 2021, and is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2022 to 2031, reaching $41,252.7…